RedHill Biopharma (RDHL) Invested Capital (2016 - 2025)
Historic Invested Capital for RedHill Biopharma (RDHL) over the last 11 years, with Q4 2024 value amounting to $7.3 million.
- RedHill Biopharma's Invested Capital fell 3704.94% to $7.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $7.3 million, marking a year-over-year decrease of 3704.94%. This contributed to the annual value of $7.3 million for FY2024, which is 3704.94% down from last year.
- Per RedHill Biopharma's latest filing, its Invested Capital stood at $7.3 million for Q4 2024, which was down 3704.94% from $11.7 million recorded in Q4 2023.
- In the past 5 years, RedHill Biopharma's Invested Capital ranged from a high of $95.2 million in Q4 2020 and a low of $7.3 million during Q4 2024
- Its 5-year average for Invested Capital is $54.7 million, with a median of $66.8 million in 2022.
- In the last 5 years, RedHill Biopharma's Invested Capital surged by 4925.49% in 2020 and then tumbled by 8256.11% in 2023.
- Quarter analysis of 5 years shows RedHill Biopharma's Invested Capital stood at $95.2 million in 2020, then decreased by 2.89% to $92.5 million in 2021, then decreased by 27.76% to $66.8 million in 2022, then plummeted by 82.56% to $11.7 million in 2023, then tumbled by 37.05% to $7.3 million in 2024.
- Its last three reported values are $7.3 million in Q4 2024, $11.7 million for Q4 2023, and $66.8 million during Q4 2022.